The plasma concentrations of Hsp90α were noted to be higher in breast cancer patients than the control group [11,15], however there are currently no clinical trials to investigate whether plasma Hsp90α could be applied to the auxiliary diagnosis of breast cancer. This evidence concerns the gene HSP90AA1 and breast carcinoma.